首页> 美国卫生研究院文献>Drug Design Development and Therapy >Characterization of renal biomarkers for use in clinical trials: biomarker evaluation in healthy volunteers
【2h】

Characterization of renal biomarkers for use in clinical trials: biomarker evaluation in healthy volunteers

机译:用于临床试验的肾脏生物标志物的表征:健康志愿者中的生物标志物评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundSeveral preclinical urinary biomarkers have been qualified and accepted by the health authorities (US Food and Drug Administration, European Medicines Agency, and Pharmaceuticals and Medical Devices Agency) for detecting drug-induced kidney injury during preclinical toxicologic testing. Validated human assays for many of these biomarkers have become commercially available, and this study was designed to characterize some of the novel clinical renal biomarkers. The objective of this study was to evaluate clinical renal biomarkers in a typical Phase I healthy volunteer population to determine confidence intervals (pilot reference intervals), intersubject and intrasubject variability, effects of food intake, effect of sex, and vendor assay comparisons.
机译:背景技术几种临床前尿液生物标志物已经获得卫生当局(美国食品和药物管理局,欧洲药品管理局以及药品和医疗器械局)的认可和接受,可以在临床前毒理学测试中检测药物引起的肾脏损伤。对其中许多生物标志物的经过验证的人体分析方法已经可以从市场上买到,并且本研究旨在表征某些新型临床肾脏生物标志物。这项研究的目的是评估典型的I期健康志愿者人群中的临床肾脏生物标志物,以确定置信区间(先导参考区间),受试者之间和受试者内部的变异性,食物摄入的影响,性别的影响以及供应商分析的比较。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号